TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders.

@article{Sun2007TLR79AA,
  title={TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders.},
  author={Siquan Sun and N. Ravi Shankar Mohd Lazim Abdullah Y. L. P. Thorani Rao and Jennifer D Venable and Robin L. Thurmond and L. K. J. Karlsson},
  journal={Inflammation & allergy drug targets},
  year={2007},
  volume={6 4},
  pages={223-35}
}
There is an increasing interest in ligands of nucleic acid-sensing Toll-like receptors (TLR), especially TLR7 and TLR9, for pharmacological intervention in various diseases. The TLR7 agonist imiquimod is currently used as a topical treatment for genital warts caused by human papillomavirus (HPV), actinic keratosis (AK) and superficial basal cell carcinoma. Oligodeoxynucleotides (ODN) TLR9 agonists are currently in clinical trials for use in lung cancer, as anti-viral therapy, as adjuvants and… CONTINUE READING